Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Trondheim – page 12

195 clinical trials in Trondheim, Norway across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Trondheim at a glance
195
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

195 trials in Trondheim

Open in trial search

Study on Durvalumab and Stereotactic Body Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vaestra Goetalandsregionen

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Mantle cell lymphoma

Not recruiting

Study of Acalabrutinib and Rituximab for Elderly Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Delirium

Not recruiting

Study on Dexmedetomidine and Clonidine Hydrochloride to Prevent Delirium in Patients Undergoing Open Heart Surgery

Registered drug
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Oslo University Hospital HF

Mantle cell lymphoma

Not recruiting

Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Oslo University Hospital HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Trondheim

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials investigating treatments for various cancer types, including pancreatic ductal cancer, gastric cancer, and follicular lymphoma. Studies focus on evaluating new therapeutic combinations and precision medicine approaches.

  • Targeted therapies for HER2-positive cancers
  • Pediatric liver tumors
  • Breast cancer personalized treatment

Multiple trials are exploring immunotherapy combinations and novel drug applications for improved patient outcomes.

02 Neurological Disorders

Research focusing on innovative treatments for Alzheimer's disease and brain tumors. Studies include evaluation of new drug combinations and comparative effectiveness of existing therapies.

  • Early-stage Alzheimer's interventions
  • Glioblastoma treatment strategies
  • Meningioma therapeutic approaches

Trials aim to improve patient outcomes through targeted therapeutic interventions and biomarker studies.

03 Respiratory and Infectious Diseases

Studies examining treatments for chronic wet cough in children and respiratory infections. Research includes antibiotic efficacy trials and innovative treatment approaches.

  • Pediatric respiratory infections
  • Antibiotic effectiveness studies
  • Wheezing prevention in children

Focus on developing evidence-based treatment protocols for respiratory conditions in pediatric populations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.